[HTML][HTML] PI3K inhibitors in inflammation, autoimmunity and cancer
AK Stark, S Sriskantharajah, EM Hessel… - Current opinion in …, 2015 - Elsevier
Highlights•Preclinical studies support us of PI3K inhibitors in autoimmunity and
inflammation.•First in class PI3K inhibitor has been approved for treatment of B cell
lymphoma.•Primary immune deficiency (APDS) caused by gain of function mutations in
PIK3CD.•PI3K inhibitors may be used to stimulate immune responses against cancer.•First
inhibitors against the class III PI3K VPS34 have been described.The healthy immune system
protects against infection and malignant transformation without causing significant damage …
inflammation.•First in class PI3K inhibitor has been approved for treatment of B cell
lymphoma.•Primary immune deficiency (APDS) caused by gain of function mutations in
PIK3CD.•PI3K inhibitors may be used to stimulate immune responses against cancer.•First
inhibitors against the class III PI3K VPS34 have been described.The healthy immune system
protects against infection and malignant transformation without causing significant damage …